Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
    (Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
    (Date:10/19/2014)... 20, 2014 OCTOBER 20-22, ... (ABIM). ABIM will take place at ... about ABIM 2014 is now available at ... representing companies and organizations from all over ... information on the latest products and developments ...
    (Date:10/19/2014)... The Asia-Pacific Speech Analytics market report defines ... analysis and forecast of revenue. This market is estimated ... million by 2019, at a Compound Annual Growth Rate ... through the TOC of the Asia-Pacific Speech Analytics market ... provided. It also provides a glimpse of the segmentation ...
    Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
    ... , , , ... BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading ... and organs, today announced the launch of its BloodStor biopreservation ... for cryopreservation of umbilical cord blood stem cells, as well ...
    ... , , , FREDERICK, Md., Aug. ... Scientist Magazine,s 2009 Top 30 Best Places to Work ... those companies with the most positive work environment, dedicated management, and innovative ... Places to Work Industry award for biotech and pharmaceutical companies. ...
    ... , , , ... Aug. 28 Avid Bioservices, Inc., a leading provider of cGMP contract ... further strengthened its executive team with the appointments of Truc Le as ... These additions reflect Avid,s recent successes in expanding its customer base ...
    Cached Biology Technology:BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 2BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 3SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies 2Avid Bioservices Expands Executive Team as it Prepares for Continued Growth 2Avid Bioservices Expands Executive Team as it Prepares for Continued Growth 3Avid Bioservices Expands Executive Team as it Prepares for Continued Growth 4Avid Bioservices Expands Executive Team as it Prepares for Continued Growth 5
    (Date:10/22/2014)... SAN JOSE, Calif. , Oct. 20, 2014 /PRNewswire/ ... with the United States Air Force Research Laboratory (AFRL), ... for Integrative Medicine (AzCIM) at the University of Arizona ... to receive research funding.  The AzCIM project,s goal is ... their ability to collect different volumes of sweat under ...
    (Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
    (Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
    Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
    ... to honey bees, neuropeptides control brain activity and, hence, our ... of a honey bee will assist researchers in understanding the ... a million neurons in the brain of a honey bee ... of the period at the end of this sentence. The ...
    ... that controls the colour of apples ?a discovery that may ... in apple skin is the result of anthocyanins, the natural ... flowers and fruits," says the leader of the CSIRO Plant ... a very important part of fruit marketing," she says. "If ...
    ... half the animal species on the planet has been re-drawn ... four major groups of insects. , Scientists have ... beetles and more distantly related to bees and wasps, contrary ... in the special Honey Bee Genome issue of the journal ...
    Cached Biology News:Scientists identify 36 genes, 100 neuropeptides in honey bee brains 2Found -- the apple gene for red 2New genetic analysis forces re-draw of insect family tree 2
    ... for RNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... DNA/RNA Aptamer Microarray Service. Probe ... Microarray contains greater than 1500 known aptamer ...
    ... Sciences provides a comprehensive epitope analysis ... synthesized on Paraflo microfluidic chips for ... development. This comprehensive service includes assistance ... using sample(s) provided by you, single ...
    ... an extension of Parkers MX80 family of positioners, ... LX80L bolt hole patterns mimic the MX80 family, ... all accessory brackets to build multi-axis systems., , ... 750 mm , Accelerations to 5 gs , ...
    ... the next step in the evolution of ... system that delivers labware to multiple laboratory ... times the throughput of ordinary microplate robots. ... variety of configurations to meet any labs ...
    Biology Products: